

Title (en)  
AUTOANTIGEN VACCINES.

Title (de)  
AUTOANTIGENE IMPFSTOFFE.

Title (fr)  
VACCINS AUTO-ANTIGENES.

Publication  
**EP 0224574 A4 19880426 (EN)**

Application  
**EP 86903969 A 19860604**

Priority  
• US 74116885 A 19850604  
• US 75684785 A 19850718

Abstract (en)  
[origin: WO8607383A1] Autoantigen vaccines are obtained by conferring antigenicity by formation of multimers, of fusion proteins to non-bacterial sequences, or both. The vaccines can be administered using conventional dosage forms for peptide vaccines, or can be supplied in a recombinant vaccinia and the peptides synthesized in situ. Particularly useful autoantigens are those derived from hormones controlling reproduction. An easily administered and reversible vaccine for preventing human pregnancy is disclosed. The vaccine comprises a vaccinia virus vector modified to contain the DNA sequence encoding the C-terminal portion (CTP) of the beta -chain of human chorionic gonadotropin, or a multimer thereof. The vaccinia vectors are designed so that the encoded antigen is expressed internally by infected cells, or the CTP-encoding sequence is modified to provide a chimera which is capable of carrying the CTPn antigen to the surface of the infected cell and either presenting the CTPn antigen at the cell surface or of secreting it. In a preferred embodiment, the influenza hemagglutinin protein, or portions thereof, are used as the components of the chimera. Similar constructions which include alternate hormone derived sequences are also effective in humans and in other mammals. The antibodies obtained against and specific for these autoantigens are also useful.

IPC 1-7  
**C12P 21/00**; **C12N 1/00**; **C07H 15/12**; **A61K 37/00**; **A61K 37/02**

IPC 8 full level  
**C07K 14/11** (2006.01); **C07K 14/59** (2006.01); **C12N 15/62** (2006.01); **C12N 15/863** (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP KR US)  
**C07K 14/005** (2013.01 - EP); **C07K 14/59** (2013.01 - EP); **C12N 15/62** (2013.01 - EP); **C12N 15/86** (2013.01 - EP); **C12P 21/00** (2013.01 - KR); **A61K 39/00** (2013.01 - EP KR US); **C07K 2319/00** (2013.01 - EP); **C07K 2319/035** (2013.01 - EP); **C07K 2319/40** (2013.01 - EP); **C12N 2710/24143** (2013.01 - EP); **C12N 2760/16122** (2013.01 - EP)

Citation (search report)  
• [Y] GB 2068971 A 19810819 - SEARLE & CO  
• [E] EP 0178867 A2 19860423 - GENENTECH INC [US]  
• [AD] NATURE, vol. 307, no. 5946, January 1984, pages 37-40, Macmillan Journals Ltd, Chesham, Bucks, GB; K. TALMADGE et al.: "Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone"  
• [A] NATURE, vol. 311, no. 5987, October 1984, pages 666-668, Reading, Berks., GB; P.H. SEEBURG et al.: "Characterization of cDNA for precursor of human luteinizing hormone releasing hormone"  
• See also references of WO 8607383A1

Cited by  
WO2014159813A1

Designated contracting state (EPC)  
AT BE CH DE FR GB IT LI LU NL SE

DOCDB simple family (publication)  
**WO 8607383 A1 19861218**; AU 5993186 A 19870107; DK 58887 A 19870403; DK 58887 D0 19870204; EP 0224574 A1 19870610; EP 0224574 A4 19880426; KR 880700077 A 19880215

DOCDB simple family (application)  
**US 8601226 W 19860604**; AU 5993186 A 19860604; DK 58887 A 19870204; EP 86903969 A 19860604; KR 870700098 A 19870204